U.S. Pharmacist Weekly News
January 25, 2023 

Survival Difference Between Torsemide, Furosemide for Heart Failure

Past studies raised the hope that torsemide would be more effective than other drugs in preventing death in heart failure patients. A clinical trial not only failed to prove that but also found little difference between the two drugs when it comes to patient survival. Learn more about the results of this trial published in the Journal of the American Medical Association.


Pfizer’s COVID Vaccine Stroke Risk in Older Recipients

One government safety system received enough reports to raise a safety concern, but public health officials from the CDC and FDA announced that there is little evidence that receipt of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent raises the risk of ischemic stroke in those aged 65 years and older. Find out what other safety systems determined.

Larger Doses of Hydroxychloroquine Increase Risk of Retinopathy

All patients with systemic lupus erythematosus—and sometimes those with other inflammatory conditions—are recommended to take hydroxychloroquine. The higher the dose of hydroxychloroquine, the more likely patients will develop retinopathy, according to a new study. Find out how researchers concluded that the overall risk for hydroxychloroquine retinopathy was 8.6% after 15 years, and most cases were mild.


COVID-19 Vaccine, Boosters Especially Important for Pregnant Women

New research strongly supports COVID-19 vaccination and boosters in pregnant women. Those expectant mothers who contracted COVID-19’s omicron variant had increased risks of maternal morbidity, severe pregnancy complications such as preeclampsia, and hospital admission, especially among symptomatic and unvaccinated women. Learn more about the results of this study led by the United Kingdom’s University of Oxford and published in Lancet.

Facebook   Twitter   USP Google App   USP itunes App
U.S. Pharmacist
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -